Corbus Pharmaceuticals (CRBP) 8-K This presentation contains certain forward-looking statements, including those relating to the Company’s

Developing Breakthrough Therapies for

Rare Inflammatory Diseases

www.CorbusPharma.com

OTCQB: CRBP

Exhibit 99.1

2

Forward-Looking Statements

This presentation contains certain forward-looking statements, including those relating to the Company’s

product development, clinical and regulatory timelines, market opportunity, competitive position, possible or

assumed future results of operations, business strategies, potential growth opportunities and other statements

that are predictive in nature.

Additional written and oral forward-looking statements may be made by the

Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The

Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.

These statements may be identified by the use of forward-looking expressions, including, but not limited to,

“expect,”

“anticipate,”

“intend,”

“plan,”

“believe,”

“estimate,”

“potential,”

“predict,”

“project,”

“should,”

“would,”

“will”

and similar expressions and the negatives of those terms.

These statements involve known and unknown

risks, uncertainties, and other factors which may cause actual results, performance or achievements to be

materially different from any future results, performance or achievements expressed or implied by the forward-

looking statements.

Prospective investors are cautioned not to place undue reliance on such forward-looking

statements, which speak only as of the date of this presentation.

The Company undertakes no obligation to

publicly update any forward-looking statement, whether as a result of new information, future events or

otherwise.

3

Overview

•

Corbus Pharma is focusing on rare, life-threatening, chronic inflammatory diseases

•

Lead drug Resunab™:  a first-in-class oral anti-inflammatory/fibrosis small-molecule

•

Acts

to

trigger

inflammatory

resolution:

the

“off”

switch

for

chronic

inflammation

•

Proven safe in Phase 1 + promising pre-clinical potency in multiple animal models

•

Phase 2 clinical trials to commence 2015:

•

Successful $10.3m private financing round (May 2014)

•

Obtained $1.3m in NIH grants

•

IP protection until 2033 and potentially longer

•

Commenced trading on OTCQB in October 2014

•

Cystic Fibrosis (CF)

•

Systemic Sclerosis (SSc) also known as “Scleroderma”

Our Target Indications: Current & Future

Indication

Patient numbers

(USA)

Estimated

Market size

Current therapies

for inflammation

Drawbacks to current

therapies

Current lead indications:

Cystic Fibrosis

30,000

>$3B

Steroids, ibuprofen

Considerable side effects

Diffuse Systemic

Sclerosis

(Scleroderma)

50,000

>$2B

Steroids,

methotrexate

Side effects, poor efficacy

Potential future indications:

Dermatomyositis

13,000

>$1B

Steroids, mAbs

Side effects, poor efficacy

Lupus (SLE)

500,000-1.5MM

>$3B

Steroids, mAbs

Side effects, poor efficacy

Idiopathic

Pulmonary Fibrosis

(IPF)

70,000

>$1B

Pirfenidone

Limited

efficacy

InterMune bought by Roche

for $8.5B (2014)

4

Inflammation

“ON”

Pro-inflammatory

Mediators

(IL6, IL8, PGE2,

LTB4)

Immune cell

TGF-ß

CB2 receptor

Inflammation

“OFF”

Fibrosis

“ON”

Fibrosis

“OFF”

•

CB2 receptor is present on immune cells and activated by endogenous lipid mediators

•

Activation of CB2 turns inflammation off (“inflammatory resolution”)

•

Resunab expected to be first CB2-binding anti-inflammatory drug to reach market

•

Upstream of other approaches: potential for better safety and potency

CB2 Receptor: Turns inflammation “off”

Immune cell

COX

LOX

LXA

4

Anti-

inflammatory

Mediators

(Lipoxins, Resolvins,

etc)

5

6

7

Resunab

7

•

Resunab: synthetic oral CB2

agonist

small-molecule

•

Designed to trigger the resolution of chronic inflammation

•

Full manufacturing, drug supply, non-clinical safety & pharmacology package for Phase 2

programs

•

Excellent clinical safety profile to date: two prior Phase 1 clinical trials (n=123)

•

Preparing to launch two Phase 2 clinical studies in H1 2015

8

Resunab:

Only

CB2-Agonist

Targeting

Inflammation

Company

Indication

Brain penetration

Status

Affects CNS

Corbus Pharma

Inflammation

Minimal

Entering

Phase 2

No

AbbVie

Pain

Full

Phase 1

Yes

Glenmark

Pain

Full

Phase 1

Yes

Eli Lilly

Knee pain

Full

Phase 2

Yes

AstraZeneca

Post operative pain

Full

Phase 2

Yes

Resunab is the only CB2 drug that can be used to treat

inflammation because it does not target the brain

9

Cystic Fibrosis

Targeting inflammation at the core of the disease

9

10

Antibiotics

Kalydeco

(for 6%) of

patients

Very limited 

treatment

No treatment

Overview: Cystic Fibrosis

10

•

Orphan

disease

(30,000

patients

in

USA,

75,000

WW)

•

Average life expectancy of CF patients is approximately 40 years

•

Inflammation at core of disease’s morbidity and mortality (pulmonary fibrosis)

•

Very high doses of steroids/ibuprofen effective but rarely used due to toxicity

•

Need for safe, chronic anti-inflammatory drug is unmet and universally recognized

•

Pharmacoeconomics support premium pricing (e.g. Kalydeco by Vertex priced at $320,000/yr)

CFTR gene

defect

Underlying

Inflammation

Infection

Fibrosis

11

Antibiotics

Kalydeco

(for 6%)

Resunab

Resunab

Resunab

targets key CF inflammatory players

11

TGF-ß

Lipoxin-A4

•

Genetically linked to disease

•

Associated with worsening symptoms

•

Absent in CF lungs

•

CFTR  defect

Underlying

Inflammation

Infection

Fibrosis

Replacement therapy effective in       

animal models

Fibrosis-inducing agent (Bleomycin) administered to lungs

day 1 followed  by daily oral Resunab for 21 days 

P<.004

Bleomycin+

Resunab

therapy

Bleomycin

Control

Gonzales et.al., Annals of Rheumatic Diseases, 2012. 71:1545-51

* Measured by hydroxyproline

Alveoli -air sacs

Resunab

Reduces Pulmonary

Fibrosis In Animal Models

Control

Bleomycin

Bleomycin

+

Resunab

(1mg/kg)

12

0

50

100

150

200

250

300

350

Resunab

Planned Cystic Fibrosis Phase 2 Trial

13

Double blind randomized placebo control study in the US and EU

Primary

endpoints:

Safety/tolerability

Secondary

endpoints:

Pharmacokinetics

and

efficacy

(FEV1,

Lung

Clearance

Index,

CFQ-R

Respiratory

Domain)

Exploratory

endpoints:

Metabolipidomic

profile

for

MOA,

biomarkers

of

disease

activity

in

blood

and

sputum,

biomarkers of inflammation, and microbiota in the lungs

Patient

number:

70

adults

with

CF

in

~20

sites

US

&

EU

Treatment

duration:

3

months

+

1

month

follow-up

Dose

response:

1

mg/day,

5

mg/day,

20

mg/day

and

2x20

mg/day

Q1 2015

Q2 2015

Q3 2015

Q4 2015

Q1 2016

Q2 2016

Q3 2016

Q4 2016

Protocol filed with FDA

X

Study launches

X

First patient dosed

X

Study duration

X

X

X

X

X

X

Last patient dosed

X

Study data released

X

Diffuse Systemic

Sclerosis

(“Scleroderma”)

Relief for a disease with no

effective long-term therapy

14

Overview: Diffuse Cutaneous Systemic Sclerosis

(Scleroderma)

15

•

Chronic inflammatory disease causing fibrosis of skin, joints and internal organs

•

Orphan disease (50,000 patients in USA)

•

80% of patients are women in their 40’s, 50’s and 60’s

•

Common cause of death: lung fibrosis (50% mortality in 10 years)

•

Early stage of disease responds to steroids/methotrexate but with serious side effects

•

No effective and safe long-term therapy available

•

Pipelines often target Idiopathic Pulmonary Fibrosis (IPF) in conjunction to SSc

Resunab

Inhibits Key Factors in SSc

•

TGF-beta plays key role in SSc progression (same in CF and IPF)

•

Elevated TGF-beta levels associated with disease progression

•

Strong Resunab efficacy data in animal models

•

Resunab

reduces

TGF-beta

and

collagen

in

skin

fibroblasts

from

SSc

patients

TGF-beta

Collagen

Concentration of Resunab

(µM)

Concentration of Resunab (µM)

Healthy skin fibroblasts

Scleroderma patients’

skin

fibroblasts

0

50

100

150

200

250

300

350

400

0

0.1

1

5

10

0

5

10

15

20

25

30

35

40

45

0

0.1

1

5

10

16

Resunab

Inhibits Skin Thickening

In Mouse SSc Model

Gonzales et.al., Annals of Rheumatic Diseases, April 4,

2012

17

Control

Bleomycin

Bleomycin

+

Resunab

Thick skin induced by

Bleomycin

Near normal skin after oral

Resunab

taken once daily

for four weeks

Healthy skin

0

100

200

300

400

500

Resunab:

Planned

SSc

Phase

2

Clinical

Trial

18

•

Double

blind

placebo

control

randomized

study

in

USA

under

IND

from

FDA

•

Primary

end

points:

Safety/tolerability

+

Change

in

clinical

outcomes

(CRISS)

•

Secondary

end

points:

Metabolipodomic

profile

+

biomarkers

of

disease

activity

&

inflammation + quality of life (QOL)

•

Patient

number:

36

adults

with

SSc

with

8-10

US

sites

•

Treatment

duration:

3

months

+

1

month

follow-up

•

Dose

response:

5mg/day,

20mg/day

and

20mg/2Xday

Q1 2015

Q2 2015

Q3 2015

Q4 2015

Q1 2016

Q2 2016

Q3 2016

Q4 2016

Protocol filed with

FDA

X

Study launches

X

First patient dosed

X

Study duration

X

X

X

X

X

X

Last patient dosed

X

Study data released

X

Management Team

19

•

Rheumatologist and immunologist.  Previously held positions in industry: SVP and Head, R&D

for Stiefel a GSK company, VP and Head of Inflammation Clinical Development at UCB and

MedImmune/AstraZeneca, and Director, Medical Affairs, Amgen

•

Former CFO: InVivo (NVIV), Celsion (CLSN), Transport Pharma, Echo Therapeutics (ECTE) &

Anika Therapeutics (ANIK)

•

Key

member

of

project

teams

which

developed

the

following

marketed

drugs:

Taxol®

(Ovarian

Cancer,

2000

peak

sales

of

$1.6B),

Orencia®

(RA,

2013

sales

of

$1.4B),

Rebif®

(MS,

2013

sales

of

$2.59B),

Gonal-F®

(Fertility,

2013

sales

of

$815MM)

•

Former VP USA Research & Operations, EMD Serono; Sr. Investigator, Bristol-Myers Squibb

•

Expertise in developing anti-inflammatory drugs including for CF

•

Co-founder and former President of Celsus Therapeutics (CLTX)

Mark Tepper, Ph.D. - President & Chief Scientific Officer

Yuval Cohen, Ph.D. - Chief Executive Officer

Sean Moran, C.P.A. M.B.A. - Chief Financial Officer

Barbara White, M.D. - Chief Medical Officer

Board of Directors

20

Yuval

Cohen,

Ph.D.

-

Chief

Executive

Officer

Avery W. (Chip) Caitlin

Renu Gupta, M.D.

David Hochman

Amb.

Alan

Holmer

-

Chairman

of

the

Board

•

CFO Celldex Therapeutics (CLDX) since 2000

•

Raised over $415MM financing

•

20 years experience in industry: Repligen (CFO) and Endogen (CFO)

•

25 years of development, regulatory and senior management experience in the biopharm industry

•

Former

CMO

of

Insmed,

a

specialty

CF

company

and

current

advisor

to

the

CEO

•

Former Vice President and Head of US Clinical Research and Development at Novartis (2003-2006)

•

Managing Partner of Orchestra Medical Ventures

•

Over 17 years of venture capital and investment banking experience

•

Former Managing Director of Spencer Trask Ventures, Inc. securing over $420 million in equity capital

•

Former CEO of PhRMA (1996-2005)

•

Over

two

decades

of

public

service

in

Washington,

D.C.

including

Special

Envoy

to

China

(2007-2009)

•

Former board member Inspire Pharma (sold to Merck for $430m in 2011)

•

Chairman of the Board of the Metropolitan Washington, D.C. Chapter of the Cystic Fibrosis Foundation

World Class Scientific Advisors

Sumner

Burstein,

Ph.D.

-

UMass

Medical

School

Professor of Biochemistry and Pharmacology; inventor of Resunab

Michael

Knowles,

M.D.,

Ph.D.

-

UNC

Chapel

Hill

Professor of Pulmonary and Critical Care Medicine

James

Chmiel,

M.D.

-

Case

Western

Reserve

Medical

School

Professor Medicine, National PI on largest ever anti-inflammatory CF study

Robert

Spiera

M.D.

-

Hospital

for

Special

Surgery

NYC

Professor of Medicine, Head of Scleroderma and Vasculitis Center

Daniel

Furst,

M.D.

-

UCLA

School

of

Medicine

Director of UCLA Scleroderma Program

Robert

Zurier,

M.D.

-

UMass

Medical

School

Ex-Chair of Rheumatology

21

Financial Profile

OTCQB: CRBP

22

Stock Ticker:

OTCQB: CRBP

$77,400,000

Market

capitalization

as

of

November 5,

2014

$10,300,000

Raise from successful private placement (Q2 2014) from institutional and retail

base

25,800,000

Common shares outstanding

41,500,000

Fully diluted shares outstanding (including warrants and stock options)

$11,400,000

Available from exercise of callable warrants

NASDAQ

Up-listing  to NASDAQ planned by Q-1 2015

Q1 2015

File IND

with FDA

Q1+Q2

2015

Q1 2015

Plan to

up-list to

NASDAQ

H2 2016

Data from

clinical

trials

2014

2016

Oct 2014

Began

trading on

OTCQB

2015

Launch

clinical

trials

Corbus Poised for Significant Upside

23

Recent Deals

Date

Company

Partner

Type

Drug

Indication

Stage

Up-Front

Deal Total

11/2014

Galecto

BMS

Option to

acquire 

TD139

Idiopathic pulmonary fibrosis

Phase 1

NA

$444M*

8/2014

InterMune

Roche

Acquisition

Esbriet

Idiopathic pulmonary fibrosis

Approved

NA

$8.3B*

9/2013

Galapagos

AbbVie

License

GLPG1837

Mutations in CF patients,

including F508del and G551D

Pre-clinical

$45M*

$405M*

7/2011

Amira

BMS

Acquisition

AM152

Idiopathic pulmonary fibrosis

and systemic sclerosis

Phase 1

$325M*

$475M*

* Figures from company press releases

$405

$444

$450

$8,300

$100

$1,000

$10,000

Galapagos       

(License -

AbbVie)

Galecto                  

(M&A -

BMS)

Amira                     

(M&A -

BMS)

Intermune           

(M&A -

Roche)

Recent Deals in CF and Fibrosis

Pre-Clinical

Phase 1

Phase 3

Potential Value Indicators

24

Recent IPO

Date

Company

Lead Compound

Indication

Stage

Market Cap

9/2014

ProQR

QR-010

Cystic Fibrosis -

RNA repair

Pre-clinical

$284.11M

* Figures from company press releases

** Leerink analyst report

Market Cap of CF

and Fibrosis Focused Companies

$286

$685

$1,347

$5,335

$26,000

$77

30

300

3000

30000

Corbus

ProQR

Insmed

PTC

Intercept

Vertex

Market

Phase 3

PC

Phase 2a

Approved Products

Company

Drug

Indication

Cost per Year

2018 Sales Est.

Vertex

Kalydeco

Cystic Fibrosis -

mutations of CFTR gene: G551D, G1244E,

G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R

$294,000

$1.2B**

Conclusions

•

Lead Product Resunab

is a novel, safe and promisingly potent clinical

stage anti-inflammatory/anti-fibrotic drug which acts to resolve

inflammation

•

Targets multiple rare chronic inflammatory indications

•

Proven safe in two Phase 1 trials

•

Promising potency in multiple pre-clinical inflammatory/fibrotic models

•

Launch two Phase 2 trials in 2015 (Cystic Fibrosis and Scleroderma)

•

Completion of studies in 2016

•

Strong patent portfolio until 2033

25

26

100 River Ridge Drive

Norwood, MA 02062

www.CorbusPharma.com